Regencell Bioscience Holdings Limited (RGC)

RGC Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	-4.3	-5.87	-7.45	-1.35	-0.81
Depreciation & Amortization	0.75	0.77	0.6	0.03	0.01
Loss (Gain) From Sale of Assets	-	0	-	-	-
Stock-Based Compensation	0.45	0.92	2.76	-	-
Other Operating Activities	-0.31	-0.28	-0.16	-	-
Change in Other Net Operating Assets	-0.59	-0.51	-1.02	0.55	0.08
Operating Cash Flow	-4	-4.96	-5.27	-0.77	-0.73
Capital Expenditures	-0.01	-0.03	-0.78	-	-0.12
Sale of Property, Plant & Equipment	-	0	-	-	-
Investment in Securities	5.25	0.09	-10	-	-
Investing Cash Flow	5.24	0.06	-10.78	-	-0.12
Short-Term Debt Issued	-	-	-	0.61	0.99
Total Debt Issued	-	-	-	0.61	0.99
Short-Term Debt Repaid	-	-	-0.43	-	-
Total Debt Repaid	-	-	-0.43	-	-
Net Debt Issued (Repaid)	-	-	-0.43	0.61	0.99
Issuance of Common Stock	-	-	22.67	-	-
Other Financing Activities	0.1	0.13	0.16	-0.17	-
Financing Cash Flow	0.1	0.13	22.41	0.44	0.99
Foreign Exchange Rate Adjustments	0.05	-0.08	-	-	-
Net Cash Flow	1.4	-4.85	6.36	-0.33	0.14
Free Cash Flow	-4.01	-4.99	-6.05	-0.77	-0.84
Free Cash Flow Per Share	-0.31	-0.38	-0.47	-0.08	-0.08
Levered Free Cash Flow	-1.88	-2.28	-2.69	-0.28	-0.52
Unlevered Free Cash Flow	-1.88	-2.28	-2.69	-0.28	-0.52
Change in Net Working Capital	0.13	0.03	0.51	-0.55	-0.1

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q